| |
Age at Onset
|
Age at Death
|
Pathology Diagnosis
|
APOE
|
Braak Stage
|
Thal Phase
|
CERAD Score
|
IHC
|
Biochem
|
|---|
|
LBD
|
|
Case 1
|
71
|
81
|
LBD/AD/CAA
|
ε3/ε3
|
V-VI
|
5
|
C3
|
A, C, M
|
–
|
|
Case 2
|
60
|
68
|
LBD/AD/CAA
|
ε3/ε4
|
VI
|
5
|
C3
|
A, C, M
|
C
|
|
Case 3
|
70
|
83
|
LBD/AD
|
ε3/ε4
|
VI
|
5
|
C3
|
A, C, M
|
–
|
|
Case 4
|
70
|
80
|
LBD/AD
|
ε3/ε3
|
III
|
3
|
C2
|
A, C, M
|
–
|
|
Case 5
|
73
|
80
|
LBD/AD
|
ε3/ε4
|
VI
|
5
|
C3
|
A, C, M
|
MTL
|
|
Case 6
|
51
|
62
|
LBD/AD
|
ε3/ε3
|
II
|
5
|
C3
|
A, C, M
|
–
|
|
Case 7
|
63
|
67
|
LBD/AD
|
ε3/ε4
|
III
|
4
|
C3
|
A, C, M
|
A, MTL
|
|
Case 8
|
62
|
67
|
LBD/AD
|
ε3/ε4
|
III
|
3
|
C1
|
A, C, M
|
–
|
|
Case 9
|
84
|
90
|
LBD/AD
|
ε3/ε3
|
III
|
5
|
C2
|
A, C, M
|
–
|
|
Case 10
|
67
|
72
|
LBD/AD
|
ε2/ε3
|
V-VI
|
3
|
C2
|
–
|
C
|
|
Case 11
|
59
|
66
|
LBD/AD/CAA
|
ε3/ε4
|
IV
|
2
|
C3
|
–
|
C
|
|
Case 12
|
40
|
78
|
LBD/AD/CAA
|
ε3/ε3
|
IV
|
3
|
C3
|
–
|
MTL
|
|
Case 13
|
64
|
74
|
LBD/AD/CAA
|
ε2/ε4
|
VI
|
5
|
C2
|
–
|
MTL
|
|
Case 14
|
62
|
68
|
LBD/AD
|
ε4/ε4
|
V
|
3
|
C3
|
–
|
MTL
|
|
AD/ALB
|
|
Case 15
|
(> 90)
|
(> 90)
|
AD/CAA
|
ε2/ε3
|
V-VI
|
3
|
C3
|
A, C, M
|
–
|
|
Case 16
|
–
|
82
|
AD
|
ε2/ε3
|
III
|
3
|
C1
|
A, C, M
|
–
|
|
Case 17
|
58
|
63
|
AD
|
ε3/ε3
|
VI
|
3
|
C3
|
A, C, M
|
–
|
|
Case 18
|
75
|
83
|
AD/CAA
|
ε3/ε4
|
V
|
3
|
C2
|
A, C, M
|
–
|
|
Case 19
|
62
|
77
|
AD/PSP
|
–
|
II
|
3
|
C2
|
A, C, M
|
–
|
|
Case 20
|
57
|
64
|
AD/CAA
|
ε3/ε3
|
V
|
5
|
C3
|
A, C, M
|
MTL
|
|
Case 21
|
40
|
77
|
AD/CAA
|
ε2/ε3
|
II
|
2
|
C2
|
A, C, M
|
MTL
|
|
Case 22
|
(> 90)
|
(> 90)
|
AD/CAA
|
ε3/ε3
|
VI
|
4
|
C3
|
A, C, M
|
–
|
|
Case 23
|
53
|
67
|
AD
|
ε3/ε3
|
VI
|
3
|
C3
|
A, C, M
|
–
|
|
Controls
|
|
Case 24
|
–
|
87
|
No neurological diagnosis
|
ε2/ε3
|
0
|
0
|
0
|
–
|
MTL
|
|
Case 25
|
56
|
67
|
FTLD-TDP
|
ε3/ε3
|
0
|
0
|
0
|
–
|
MTL
|
|
Case 26
|
–
|
82
|
Cerebrovascular arteriolosclerosis
|
ε2/ε3
|
II
|
2
|
C1
|
–
|
C
|
|
Case 27
|
–
|
52
|
No neurological diagnosis
|
ε3/ε4
|
II
|
2
|
C1
|
–
|
C
|
- LBD Lewy body dementia, AD Alzheimer’s disease, AD/ALB Alzheimer’s disease with Amygdala restricted Lewy bodies, CAA cerebral amyloid angiopathy, PSP progressive supranuclear palsy, FTLD-TDP frontotemporal lobar degeneration with TAR DNA-binding protein 43 inclusions, APOE apolipoprotein E, A amygdala, C cingulate cortex, M midbrain, MTL medial temporal lobe
